1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.
2. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions: patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, certain diarrheal states; and long-term corticosteroid therapy.
3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. However, serum potassium should still be checked periodically. If hypokalemia occurs, dietary supplementation with potassium-rich foods may be adequate to control milder cases. In more severe cases, supplementation with potassium salts such as Effer-K® may be indicated.
The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.
The most severe adverse effect is hyperkalemia. If hyperkalemia is suspected, contact your healthcare provider or go to the emergency room immediately.
Manufactured by Nomax Inc. Made in the USA
Warning: In patients with hyperkalemia and impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest.
Note: Effer-K is not equivalent to KCl. It is potassium citrate in solution, not potassium chloride. While potassium citrate can be used to elevate potassium levels, it is not recommended for patients who have metabolic alkalosis or acid/base disorders. It may result in the alteration of the acid/base balance.